ReviewJournal of experimental & clinical cancer research : CR2017
Curcumin: the spicy modulator of breast carcinogenesis.
Review in Journal of experimental & clinical cancer research : CR, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 3 syntheses or guidelines pooled it, 156 citations in OpenAlex.
- A Systematic Review and Meta-Analysis of the Metal Nano-Particles Loaded with Herbal Drugs Moieties Against Breast Cancer.Recent patents on nanotechnology · 2025Pooled it
- Guideline
- Pooled it
- Analysis of Curcumin as a Radiosensitizer in Cancer Therapy with Serum Survivin Examination: Randomised Control Trial.Asian Pacific journal of cancer prevention : APJCP · 2021Trial
- Effects of Common Food Additives Kappa-, Iota- and Lambda-Carrageenans on Intestinal Epithelial Cell Activation and Barrier Disruption.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2026Article
- Plant Bioactive Constituents and Their Potential Benefits in HPV-Positive Oropharyngeal Squamous Cell Carcinoma-A Narrative Review.Current issues in molecular biology · 2026Review
- Interplay of Interleukin-1Oncology research · 2026Article
- Natural products as therapeutic interventions for inflammation-mediated cancer.Discover oncology · 2025Review
- Targeting mTOR with curcumin: therapeutic implications for complex diseases.Inflammopharmacology · 2025Review
- Telomere Length as Both Cause and Consequence in Type 1 Diabetes: Evidence from Bidirectional Mendelian Randomization.Biomedicines · 2025Article
- Curcumin, an active component of turmeric: biological activities, nutritional aspects, immunological, bioavailability, and human health benefits - a comprehensive review.Frontiers in immunology · 2025Review
- Folate-Modified Curcumin-Loaded Nanoparticles for Overcoming Delivery Challenges in Cancer Treatment: A Narrative Review.Current pharmaceutical biotechnology · 2025Review
- Curcumin attenuates smoking and drinking activated NF-κB/IL-6 inflammatory signaling axis in cervical cancer.Cancer cell international · 2024Article
- Curcumin-Dichloroacetate Hybrid Molecule as an Antitumor Oral Drug against Multidrug-Resistant Advanced Bladder Cancers.Cancers · 2024Article
- Synthesis, pharmacological evaluation, andHeliyon · 2024Article
- Potential Role of Phytochemicals as Glucagon-like Peptide 1 Receptor (GLP-1R) Agonists in the Treatment of Diabetes Mellitus.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Article
- DeepFGRN: inference of gene regulatory network with regulation type based on directed graph embedding.Briefings in bioinformatics · 2024Article
- Curcumin in Cancer Prevention: Insights from Clinical Trials and Strategies to Enhance Bioavailability.Current pharmaceutical design · 2024Review
- Mechanistic insight of curcumin: a potential pharmacological candidate for epilepsy.Frontiers in pharmacology · 2024Review
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Worldwide breast cancer is the most common cancer in women. For many years clinicians and the researchers are examining and exploring various therapeutic modalities for breast cancer. Yet the disease has remained unconquered and the quest for cure is still going on. Present-day strategy of breast cancer therapy and prevention is either combination of a number of drugs or a drug that modulates multiple targets. In this regard natural products are now becoming significant options. Curcumin exemplifies a promising natural anticancer agent for this purpose. This review primarily underscores the modulatory effect of curcumin on the cancer hallmarks. The focus is its anticancer effect in the complex pathways of breast carcinogenesis. Curcumin modulates breast carcinogenesis through its effect on cell cycle and proliferation, apoptosis, senescence, cancer spread and angiogenesis. Largely the NFkB, PI3K/Akt/mTOR, MAPK and JAK/STAT are the key signaling pathways involved. The review also highlights the curcumin mediated modulation of tumor microenvironment, cancer immunity, breast cancer stem cells and cancer related miRNAs. Using curcumin as a therapeutic and preventive agent in breast cancer is perplexed by its diverse biological activity, much of which remains inexplicable. The information reviewed here should point toward potential scope of future curcumin research in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.